Keryx Biopharmaceuticals (NASDAQ:KERX)’s share price fell 5.5% on Wednesday . The company traded as low as $4.66 and last traded at $4.66. 1,573,383 shares traded hands during trading, an increase of 34% from the average session volume of 1,172,449 shares. The stock had previously closed at $4.93.

A number of research firms recently weighed in on KERX. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, December 1st. ValuEngine cut shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, November 10th. Finally, Stifel Nicolaus lowered their price objective on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating for the company in a research report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $7.44.

The company has a debt-to-equity ratio of 13.95, a quick ratio of 3.76 and a current ratio of 4.46. The stock has a market cap of $553.38, a PE ratio of -3.11 and a beta of 4.92.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.03). Keryx Biopharmaceuticals had a negative net margin of 323.92% and a negative return on equity of 10,954.62%. The business had revenue of $15.00 million during the quarter, compared to analysts’ expectations of $18.88 million. During the same period in the prior year, the business earned ($0.39) EPS. The business’s quarterly revenue was up 138.1% on a year-over-year basis. equities analysts anticipate that Keryx Biopharmaceuticals will post -1.35 EPS for the current year.

In other Keryx Biopharmaceuticals news, COO Christine A. Carberry sold 9,048 shares of the firm’s stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $4.87, for a total value of $44,063.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 20,232 shares of company stock valued at $107,597 in the last three months. 2.58% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of KERX. Schwab Charles Investment Management Inc. boosted its position in Keryx Biopharmaceuticals by 1.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 441,106 shares of the biopharmaceutical company’s stock valued at $3,190,000 after buying an additional 4,388 shares during the period. Rhumbline Advisers boosted its position in Keryx Biopharmaceuticals by 0.3% in the 2nd quarter. Rhumbline Advisers now owns 99,711 shares of the biopharmaceutical company’s stock valued at $721,000 after buying an additional 335 shares during the period. Bank of New York Mellon Corp boosted its position in Keryx Biopharmaceuticals by 3.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 963,054 shares of the biopharmaceutical company’s stock valued at $6,963,000 after buying an additional 32,687 shares during the period. Legal & General Group Plc boosted its position in Keryx Biopharmaceuticals by 8.5% in the 2nd quarter. Legal & General Group Plc now owns 28,205 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 2,220 shares during the period. Finally, Principal Financial Group Inc. boosted its position in Keryx Biopharmaceuticals by 4.2% in the 2nd quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 590 shares during the period. 64.91% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Keryx Biopharmaceuticals (KERX) Shares Down 5.5%” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://theolympiareport.com/2018/01/24/keryx-biopharmaceuticals-kerx-shares-down-5-5.html.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.